Satellos Bioscience Inc. (TSX:MSCL)
Canada · Delayed Price · Currency is CAD 12.34
+0.17 (1.40%)
Sep 24, 2026, 3:40 PM EST
Satellos Bioscience Employees
As of December 31, 2025, Satellos Bioscience had 21 total employees, including 18 full-time and 3 part-time employees. The number of employees increased by 4 or 23.53% compared to the previous year.
Employees
21
Change (1Y)
4
Growth (1Y)
23.53%
Revenue / Employee
n/a
Profits / Employee
-2.46M CAD
Market Cap
261.81M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | 4 | 23.53% | 18 | 3 |
| Dec 31, 2024 | 17 | 1 | 6.25% | 14 | 3 |
| Dec 31, 2023 | 16 | - | - | 4 | 12 |
Satellos Bioscience News
- 21 hours ago - Satellos announces U.S. FDA cleared IND application for forazapadin - TheFly
- 21 hours ago - Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development - GlobeNewsWire
- 8 days ago - Satellos Bioscience Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 9 days ago - Satellos to Present at the 31st Annual Congress of the World Muscle Society - GlobeNewsWire
- 14 days ago - Satellos Bioscience Slides: Corporate presentation - Filings
- 15 days ago - Satellos Bioscience Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 15 days ago - Satellos Bioscience (MSLE) Gains INN for Forazapadin Amid Unprofitable Status and Mixed Market ... - GuruFocus
- 15 days ago - Satellos Names Forazapadin As INN For Lead DMD Drug Candidate - Nasdaq